Solana ETF 获批前景:从「几乎无望」到「2025 年底前可期」,当前有哪些挑战?

Oncimmune

company

About

Oncimmune engaged in developing and commercializing its EarlyCDT platform technology.

  • Nottingham,Nottingham,United Kingdom
  • 101 - 250

Details

Last Funding Type
Post-IPO Equity
Last Funding Money Raised
£5M
Industries
Biotechnology,Commercial
Founded date
Jan 1, 2006
Number Of Employee
101 - 250
Operating Status
Active
Stock Symbol
lse:ONC

Oncimmune (USA) LLC, founded in 2006, is an industry leader in early cancer detection. Oncimmune LLC is a wholly-owned subsidiary of Oncimmune LTD based in Nottingham, England. The company is committed to advancing early cancer detection through proprietary autoantibody assay technologies based on biological technology initially identified by John Robertson, M.D., professor of surgery at Nottingham University, England, and chief scientific officer of Oncimmune LTD. Ongoing research and development is conducted by Oncimmune under the direction of Dr. Robertson. The company’s mission is to develop early cancer detection tests to identify more than 90 percent of solid-tumor cancers, which make up 70 percent of all cancers including lung, breast, colorectal, prostate, stomach, pancreatic and ovarian. As a lab service, Oncimmune’s metro Kansas City laboratory is CLIA-certified under the Clinical Laboratory Improvements Amendment of 1988. Oncimmune LTD owns a portfolio of patents including No. 7,402,403 and No. 7,205,117.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
5
£5.09M
Oncimmune has raised a total of £5.09M in funding over 2 rounds. Their latest funding was raised on Sep 27, 2017 from a Post-IPO Equity round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Sep 27, 2017 Post-IPO Equity £5M Detail
Feb 1, 2017 Grant £94K 1 SBRI Healthcare Detail
Mar 27, 2016 IPO Detail
Dec 31, 2014 Debt Financing 1 Detail
Oct 1, 2007 Series Unknown 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
3
Oncimmune is funded by 3 investors. SBRI Healthcare and Claret Capital Partners are the most recent investors.
Investor Name Lead Investor Funding Round
SBRI Healthcare Yes Grant
Claret Capital Partners Debt Financing
Balderton Capital Series Unknown

Employee Profiles

Number of Employee Profiles
5
Oncimmune has 5 current employee profiles, including Executive Matthew Luttrell
Executive
Executive
Executive
Executive
Executive

Acquisition

Oncimmune has acquired 1 organizations. Their most recent acquisition was Protagen on Mar 19, 2019. They acquired Protagen for £4.10M.

Date Company Name
Industry Acquisition Type Price
Mar 19, 2019 Protagen
Biotechnology acquisition £ 4.10M Detail